A recent study reveals that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who halt conventional diet and exercise regimens.
Findings released in a leading health publication points out that while obese people frequently drop substantial amounts of their total mass while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals using such treatments need to be cognizant of the danger of rapid weight regain when the medication is stopped," stated researcher Dr. Susan Jebb.
Such speed of regain suggests a return to original weight within about a year and a half.
Comparing Approaches
The study, which reviewed dozens of studies involving thousands of participants, contrasted the results of GLP-1 agonists with other pills.
The team note that people who lose weight through lifestyle changes alone typically experience a more gradual weight regain—perhaps 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Doctors suggest the mode of action of the jabs is key to understanding the heightened regain.
These medications copy a natural hormone called GLP-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than normal may cause the body to generate a reduced amount of its own natural GLP-1, and may also lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this medication leads to hunger is no longer kept in check, making excessive eating a significant risk."
A Lifelong Disease?
The NHS suggest the jabs for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Many experts say that, considering the high risk of weight regain, the therapy might need to be ongoing.
This perspective is reinforced by pharmaceutical companies, who note that the results "highlight the persistent nature of excess weight," comparing it to managing conditions like hypertension.
User Experiences
Users who have discontinued the medication report a sudden return of appetite.
"It was like a trigger that goes on and you become extremely hungry," described one woman.
This challenge is exacerbated if patients have not established permanent lifestyle or habit changes during therapy.
Significant Adoption
Figures suggest that a significant number of people in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Use is greater among women compared to males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
Finally, researchers emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent cure and maintained weight loss likely depends on ongoing lifestyle management.
